Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Ixtlapale-Carmona X et al. | Graft immunologic events in deceased donor kidney transplant recipients with preformed HLA-donor specific antibodies. | 2018 | Transpl. Immunol. | pmid:28974434 |
Felipe C et al. | Adequacy of Initial Everolimus Dose, With and Without Calcineurin Inhibitors, in Kidney Transplant Recipients. | 2018 | Ther Drug Monit | pmid:29271815 |
Kimura Y et al. | Profiling the immunotoxicity of chemicals based on in vitro evaluation by a combination of the Multi-ImmunoTox assay and the IL-8 Luc assay. | 2018 | Arch. Toxicol. | pmid:29594315 |
Tang JT et al. | A Low Fixed Tacrolimus Starting Dose Is Effective and Safe in Chinese Renal Transplantation Recipients. | 2018 | Ann. Transplant. | pmid:29735966 |
Thishya K et al. | Artificial neural network model for predicting the bioavailability of tacrolimus in patients with renal transplantation. | 2018 | PLoS ONE | pmid:29621269 |
Riva N et al. | Survival Time to Biopsy-Proven Acute Rejection and Tacrolimus Adverse Drug Reactions in Pediatric Liver Transplantation. | 2018 | Ther Drug Monit | pmid:29621122 |
Liu J et al. | Donor and recipient P450 gene polymorphisms influence individual pharmacological effects of tacrolimus in Chinese liver transplantation patients. | 2018 | Int. Immunopharmacol. | pmid:29454235 |
Choi CB et al. | Outcomes of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis. | 2018 | Lupus | pmid:29448881 |
Yoon CH et al. | Topical Tacrolimus 0.03% for Maintenance Therapy in Steroid-Dependent, Recurrent Phlyctenular Keratoconjunctivitis. | 2018 | Cornea | pmid:29309358 |
Buchholz BM et al. | Role of colectomy in preventing recurrent primary sclerosing cholangitis in liver transplant recipients. | 2018 | World J. Gastroenterol. | pmid:30065563 |